What are the common side effects during Nilotinib treatment?

Nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor, mainly used for the treatment of chronic myelogenous leukemia (CML). During treatment, patients more commonly experience hematologic side effects, such as neutropenia, thrombocytopenia, and anemia. These hematopoietic function inhibitions are mostly reversible and can usually be relieved after drug adjustment or symptomatic treatment. Regular blood routine monitoring is crucial to detect and manage such side effects in a timely manner.

The more serious side effects of nilotinib treatment include cardiovascular system problems such as angina, arrhythmias, arteriosclerosis, and thrombosis. In particular, high-risk patients such as those with a history of hypertension, hyperlipidemia, and diabetes should undergo cardiovascular evaluation before taking the drug, and closely monitor electrocardiogram and blood lipids during treatment. Reasonable control of risk factors can effectively reduce the incidence of cardiovascular events.

Patients often report gastrointestinal discomforts such as nausea, diarrhea, abdominal pain, constipation and indigestion while taking nilotinib. Most of these symptoms are mild to moderate and can be alleviated by adjusting the medication time (taking with meals) and symptomatic and supportive treatment. If symptoms are severe or persistent, you should communicate with your doctor promptly and adjust the dose if necessary.

Some patients may experience elevated liver enzymes (ALT, AST), indicating the risk of liver function damage, and liver function indicators need to be monitored regularly. In addition, rashes, headaches, fatigue and muscle pain are also common. Patients should closely observe their symptoms during the medication period and follow the doctor's instructions for regular examinations to ensure timely detection of side effects and take corresponding measures to ensure the safety and efficacy of treatment.

Reference materials:https://www.drugs.com/